AzTrials
AzTrials

Blood CancerNCT06817759

Development of an Intervention Integrating Procedures Combining Hypnosis and Virtual Reality in the Support of Patients with Hematological Cancer

A study testing Virtual Reality Hypnosis, VRH : Beach and VRH : Forest in people with Blood Cancer and Multiple Myeloma (MM), run by Ciusss de L'Est de l'Île de Montréal at 1 site in Canada.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Research into cancer patients has shown that quality of life is significantly altered by the disease and its associated treatments and is also reported to be a predictor of significant emotional distress. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Blood Cancer, Multiple Myeloma (MM), Lymphoma
What is being tested?
Virtual Reality Hypnosis, VRH : Beach and VRH : Forest
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteCanada
Study dates
Feb 2025to Dec 2025
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Being 18 years of age or older
  • Suffering from multiple myeloma or lymphoma eligible for transplant
  • Understanding French

Who cannot join

  • Deafness
  • Blindness
  • Confusion or psychopathological disorders (for example, schizophrenia) that may impair communication

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

David Ogez, Ph.D contact

514-609-4391

david.ogez@umontreal.ca

Floriane Rousseaux, Ph.D contact

438-543-1878

floriane.rousseaux@hotmail.com

Canada1 site
  • Centre de Recherche de l'Hôpital Maissonneuve-Rosemont

    Montreal, Quebec, H1T2M4

    David Ogez, Ph.D, 514-609-4391, david.ogez@umontreal.ca

    Floriane Rousseaux, Ph.D, 438-543-1878, floriane.rousseaux@hotmail.com

Other trials in Canada

About this study

Official title: Study Protocol for the Development of an Intervention Integrating Procedures Combining Hypnosis and Virtual Reality in the Support of Patients with Myeloma and Lymphoma During Stem Cell Transplant: a Pilot Randomized Clinical Trial

Research into cancer patients has shown that quality of life is significantly altered by the disease and its associated treatments and is also reported to be a predictor of significant emotional distress. Blood cancer patients are among those most affected in terms of quality of life, facing stem cell transplantation after high-dose chemotherapy, a treatment that is recognized as one of the most stressful of cancer therapy, due to the many adverse effects, including pain, and the uncertainty linked to the fear of graft failure. Hypnosis interventions are proving effective in treating common side effects: nausea, pain, fatigue, anxiety, depressive symptoms and improving overall quality of life, and other interventions, based on virtual reality, have shown promising effects on patients' distress and acute pain. The aim of this study is to evaluate the effects of an intervention program combining hypnosis and virtual reality in assisting myeloma and lymphoma patients during stem cell transplantation, with a view to improving their quality of life during this period. The project aims to assess the validity of the intervention, and to evaluate the effects of the intervention on patients' anxiety, pain and fatigue during transplantation. The validity of the intervention will be measured by a questionnaire assessing the relevance and acceptability of the intervention, expected effects, and practical implementation. Socio-demographic and clinical data will be collected from patients, including axiety, pain, fatigue and quality of life, studied at pre (one week after transplantation) and post (one month after transplantation) intervnention, and at follow-up (three month after transplantation).

Read the detailed description

This proposal aims to reduce anxiety, pain and fatigue of transplant patients and thus improve their quality of life after the end of the intervention. To do this, the investigators will build on studies of VR use in oncology, and thus address the limitations of existing virtual reality (VR) programs, by developing an intervention that combines immersive technologies derived from VR with medical hypnosis (VRH). This new VRH program involves individualized patient management using hypnosis techniques, to promote better absorption into the experience and optimal response to hypnotic suggestions for managing emotions and pain. In concrete terms, this proposal has two complementary objectives:

  1. Evaluate the effects of an VRH prototype in reducing anxiety, pain and fatigue in transplant patients, and thus improving their quality of life after the intervention.
  2. Gather user experience, satisfaction levels and recommendations for improvement of the VRH prototype from patients

Methods

Intervention: An intervention program (VRH) that combines VR and hypnosis to facilitate the patient's absorption into a safe, benevolent imaginary world, in which they will be invited to live an experience that distracts them from their negative emotions and pain (Toujours Dimanche application).

The virtual experience will be structured along the lines of a hypnosis session: 1- A soothing immersion will first be offered to catalyze absorption through gentle descents and calming audio-visual stimuli, 2- Reaching a safe, relaxing space, dreamily representing two soothing natural environments (beach or park of the patient's choice), 3- Two therapeutic stress-management activities (dropping into a bag containing all the stress the participants want to get rid of, and allowing the participants to be carried by an imaginary horse, which enables them to escape to a safe place), 4- a physical discomfort manipulation activity enabling participants to remove the sensation of discomfort from the part of their body afflicted by it, and 5- Return to an awake state of consciousness.

The application allows the patient to visit a pleasant place either by taking control of it or in a guided way accompanied by a hypnosis verbatim. The patient can choose between these two options, and the investigators document how he or she uses the application.

Participants : Sixty participants with hematological cancer undergoing stem transplantation will be included in this research. They will be randomized in the two groups of the study : VRH and control (waiting list, will have the intervention at the end of the study).

Procedures: Participants will be asked to complete self-evaluations at four measurement points: T0=pre intervention (one week after the day of transplantation), T1=first session (one week after the day of transplantation), T2= one month post-transplantation and T3=three months follow-up post-transplantation. Interviews to gather patient expectations and satisfaction levels will also be conducted at T0 and T3 respectively for patients in the VRH condition. The first session takes place after the transplant (about 1 week) and patients then use the application at their own pace. The headset then remains available for use during the following two weeks. With the application, they have access to 4 hypnosis recordings (Beach, Forest, MagicHand and SecurityProtection) as well as a bank of landscapes they can visit. They have the choice of using contemplative VRH (with hypnosis) or active VR (wandering through the landscapes on their own). How they use the application will be documented with a logbook.

Measures :

Quality of life will be documented by the FACT-BMT, a scale validated for patients undergoing bone marrow transplantation. It contains 50 items divided in 5 subscales : Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Bone Marrow Transplantation Subscale scored on a 5-points Likert scale.

The HADS, a scale validated in French for cancer, will assess participants' anxiety-depression. This scale is made up of 14 items: 7 items determine the degree of anxiety and the other 7, the degree of depression. The score of each subscale is calculated by summing the score of each item, which varies between 0 and 3, so that each subscale can reach a maximum score of 21

Pain will be assessed with the Brief Pain Inventory. This scale is made of 8 items on a 10-points Lickert scale assessing severity of pain, impact of pain on daily function, location of pain, pain medications and amount of pain relief in the past 24 hours or the past week.

Fatigue will be assessed with the Multidimensional Fatigue Inventory 10 items version (MFI-10) adapted for cancer. It is scored on a 5-points Likert Scale going form 1: "do not agree at all" to 5: "totally agree".

Ten-level Visual Numerical Scales (VNS) will also be used to assess pain, anxiety, absorption, i.e., the tendency to become totally involved in a perceptual and imaginative experience, and dissociation, i.e., a mental separation of components of the experience, fatigue and amusement.

The investigators will collect patients' levels of expectation and satisfaction through 5-level VNS (1 = "not at all satisfied", 5 = "very satisfied") and through explanatory interviews.

The Simulator Sickness Questionnaire, a scale validated in French assesses cybersickness symptoms related to VR immersion. It contains 16 items divided in two subsacles: nausea and oculomotor, which the participant must qualify with "not at all" (scored 0) , "a little" (scored 1), "moderately" (scored 2) or "severely" (scored 3).

Analyses : Continuous quantitative variables will be expressed as mean +/- standard deviation, and categorical variables as headcounts and percentages. Statistical analyses will be performed using jamovi 2.3.18 software with a threshold α = 0.05.

Quantitative analysis

After checking for applicability, in order to evaluate the effectiveness of the intervention in the experimental group compared to the control group, a MANOVA will be performed. The dependent variables are anxiodepressive symtoms, pain, quality of life and fatigue, and the independent variables are the different measurement times. The investigators will control for age, gender, socioeconomic status, diagnosis absorption, dissociation, and amusement, . If suitable, the investigators will make post-hoc comparisons to compare scores between groups and at each measurement time with a Bonferroni correction.

Correlations will be performed on variables measured during the transplant phase (anxiety, pain, fatigue, absorption, dissociation, amusement) to measure the immediate effects of VRH. Correlations will be made between pre- and post-intervention scores and will be estimated with Pearson's or Spearman's correlation and their 95 % CI. Correlations will also be made between primary and secondary outcomes.

The investigators expect better effects on primary outcomes, i.e., diminution of anxiety and pain levels and secondary outcomes, i.e., quality of life and fatigue for the VRH program than for condition C.

Qualitative analysis

The verbatims from the semi-structured interviews will be analyzed qualitatively using NVivo software. The software enables thematic content analysis, highlighting codes in the text and graphically grouping them into themes to create a thematic tree. To identify the key themes in patients' explicit discourse, a general inductive method inspired by Braun and Clarke (2021) will be employed, aiming to uncover recurring patterns directly from the data. This data-driven approach involves deriving themes organically from the dataset. The recommended process involves six main steps after preparing the raw data files (e.g., formatting and correcting transcription errors): 1) thoroughly reading the transcripts to become familiar with the data, 2) conducting line-by-line coding to generate initial codes, 3) identifying recurring themes, 4) reviewing and refining these themes, 5) defining and naming each theme, and 6) producing a report that incorporates verbatim examples.

Being tested
Virtual Reality Hypnosis, VRH : Beach, VRH : Forest, VRH : MagicHand, VRH : SecurityProtection
Keywords
Virtual reality hypnosis, Quality of life, Blood cancer, Oncology, multiple myeloma, lymphoma, hypnosis, virtual reality, hematology, anxiety, pain, stem cells transplantation
Medical subject headings
Hematologic Neoplasms, Multiple Myeloma, Lymphoma, Neoplasms, Anxiety Disorders, Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Virtual Reality HypnosisDevice

    An intervention program (VRH) that combines VR and hypnosis; Can use it whenever and how much they want. It contains 200 landscapes in VR and 4 different VRH sessions

  • VRH : BeachDevice

    Hypnosis session with a VR immersion at the beach; one accompanied session

  • VRH : ForestDevice

    Hypnosis session with a VR immersion in forests; one accompanied session

  • VRH : MagicHandDevice

    Hypnosis session with a VR immersion with techniques to reduce pain; one accompanied session

  • VRH : SecurityProtectionDevice

    Hypnosis session with a VR immersion with techniques to reduce anxiety; one accompanied session

Study groups in NCT06817759
Study groupRoleWhat they receive
Intervention (VRH) groupExperimentalFour obligatory accompanied session of VRH and use of VRH as needed.
Receives: Device: Virtual Reality Hypnosis; Device: VRH : Beach; Device: VRH : Forest; Device: VRH : MagicHand; Device: VRH : SecurityProtection
Control groupNo interventionStandard of care (waiting list, will receive VRH following the study).

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Anxiety and depression

    Anxiety-depression will be measured using the Hospital anxiety and depression scale (HADS), a scale validated in French for cancer. This scale is made up of 14 items: 7 items determine the degree of anxiety and the other 7, the degree of depression. The score of each subscale is calculated by summing the score of each item, which varies between 0 and 3, so that each subscale can reach a maximum score of 21

    Measured: Studied one week, one month and three months post-transplantation

  2. Level of pain

    Pain will be assessed with the Brief Pain Inventory. This scale is made of 8 items on a 10-points Lickert scale (0=no pain, 10=worst pain) assessing severity of pain, impact of pain on daily function, location of pain, pain medications and amount of pain relief in the past 24 hours or the past week.

    Measured: Studied one week, one month and three months post-transplantation

Secondary outcomes (11)
  1. Level of quality of life

    Quality of life will be assessed by FACT-BMT, which comprises 50 items in 5 subscales : Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Bone Marrow Transplantation Subscale scored on a 5-points Likert scale (0=not at all, 4=very much).

    Measured: Studied one week, one month and three months post-transplantation

  2. Absorption

    Absorption will be measured using a eleven-level Visual Numerical Scales (VNS) (minimum 0=no absoption at all, maximum 10=totally absorbed)

    Measured: Studied immediately before and after each use of the intervention 4 times during the two weeks in possession of the VR headset.

  3. Dissociation

    Dissociation will be measured using a eleven-level Visual Numerical Scales (VNS) (minimum 0=no dissociation, maximum 10=fully dissociated).

    Measured: Studied immediately before and after each use of the intervention 4 times during the two weeks in possession of the VR headset.

  4. Level of expectation and satisfaction

    Level of expectation and satisfaction will be assessed using a five-level Visual Numerical Scales (VNS) (1 = "not at all satisfied", 5 = "very satisfied") and semi-structured interviews

    Measured: Measured respectively one week post-transplantation and three months post-transplantation

  5. Cybersickness

    Cybersickness will be measured using the Simulator Sickness Questionnaire (SSQ), a scale validated in French assesses cybersickness symptoms related to VR immersion. It contains 16 items divided in two subsacles: nausea and oculomotor, which the participant must qualify with "not at all" (scored 0) , "a little" (scored 1), "moderately" (scored 2) or "severely" (scored 3).

    Measured: Measured after each use of the intervention 4 times during the two weeks in possession of the VR headset.

  6. Amusement

    Amusement will be measured using a eleven-points Visual Numerical Scales (VNS) (minimum 0=no amusement, maximum 10=very amused)

    Measured: Studied immediately before and after each use of the intervention 4 times during the two weeks in possession of the VR headset.

  7. Level of pain

    Pain will be assessed using a Visual Numerical Scales (VNS) (minimum 0=no pain at all, maximum 10=very painful)

    Measured: Studied immediately before and after each use of the intervention 4 times during the two weeks in possession of the VR headset.

  8. Fatigue

    Fatigue will be assessed with the Multidimensional Fatique Inventory 10 items version (MFI-10), a scale adapted for cancer. It is scored on a 5-points Likert Scale going form minimum 1: "do not agree at all" to maximum 5: "totally agree".

    Measured: Studied one week, one month and three months post-transplantation

  9. Anxiety

    Anxiety will be measured using a eleven-level Visual Numerical Scales (VNS) (minimum 0=not anxious at all, maximum10= very anxious)

    Measured: Studied immediately before and after each use of the intervention 4 times during the two weeks in possession of the VR headset.

  10. Fatigue

    Fatigue will be measured using a ten-level Visual Numerical Scales (VNS) (minimum 0= no fatigue at all, maximum 10=very fatigued)

    Measured: Studied immediately before and after each use of the intervention 4 times during the two weeks in possession of the VR headset.

  11. Relaxation

    Relaxation will be measured using a eleven-points Visual Numerical Scales (VNS) (minimum 0=not relaxed at all, maximum 10=relaxed)

    Measured: Studied immediately before and after each use of the intervention 4 times during the two weeks in possession of the VR headset.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Feb 2025
  2. Study startFeb 2025 (estimated)
  3. Primary completionSep 2025 (estimated)
  4. Study completionDec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Model description
participants will be recruited and randomly assigned to two conditions: VRH, and a control condition (C) (waiting-list, will receive the intervention after the end of the study)
Masking
None (open label)
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06817759
Sponsor's protocol ID
2023-3251
Status last verified
Feb 2025
First submitted
27 Jan 2025
Last updated
10 Feb 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: All IPD that underlie results in a publication will be shared in a dedicated OSF repository.

Publications

  • Laurin A, Rousseaux F, Fournier V, Roy J, Landry M, LeBlanc R, Godin N, Arbour C, Richebe P, Jerbi K, Rainville P, Ogez D. Using virtual reality hypnosis during stem cell transplant for patients in hematology: A protocol for a feasibility randomized study. PLoS One. 2026 Feb 27;21(2):e0338617. doi: 10.1371/journal.pone.0338617. eCollection 2026.

    PubMed 41758815

Questions about this trial

What is this clinical trial studying?

A study testing Virtual Reality Hypnosis, VRH : Beach and VRH : Forest in people with Blood Cancer and Multiple Myeloma (MM), run by Ciusss de L'Est de l'Île de Montréal at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 10 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact David Ogez, Ph.D (514-609-4391, david.ogez@umontreal.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Anxiety and depression (time frame: Studied one week, one month and three months post-transplantation). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06817759, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Feb 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in